Readily available biomarkers predict poor survival in metastatic pancreatic cancer.

Autor: Strijker M; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van Veldhuisen E; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van der Geest LG; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands., Busch OR; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Bijlsma MF; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Haj Mohammad N; Department of Medical Oncology, University Medical Center, Utrecht University, Utrecht, The Netherlands., Homs MY; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., van Hooft JE; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands., Verheij J; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., de Vos-Geelen J; Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Wilmink JW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Steyerberg WEW; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Besselink MG; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van Laarhoven HW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2021 Jun; Vol. 26 (4), pp. 325-334. Date of Electronic Publication: 2021 Mar 21.

WITHDRAWN: Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.

Autor: Homs MY; Dept. of Gastroenterology & Hepatology, Erasmus MC / University Medical Center Rotterdam, P.O. Box 2040, Rotterdam, Netherlands, 3000 CA., van der Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ

Publikováno v: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2010 May 12 (5). Cochrane AN: CD004063. Date of Electronic Publication: 2010 May 12.

Emerging drugs for esophageal cancer.

Autor: Homs MY; University Medical Center Utrecht, Department of Medical Oncology, P.O. Box 85500, 3508 GA Utrecht, The Netherlands., Voest EE, Siersema PD

Publikováno v: Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2009 Jun; Vol. 14 (2), pp. 329-39.

Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.

Autor: Homs MY; Erasmus MC, Dept. of Gastroenterology & Hepatology, University Medical Center, PO Box 2040, Rotterdam, Netherlands., v d Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ

Publikováno v: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2006 Oct 18 (4). Cochrane AN: CD004063. Date of Electronic Publication: 2006 Oct 18.

A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients.

Autor: Verschuur EM; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, The Netherlands., Homs MY, Steyerberg EW, Haringsma J, Wahab PJ, Kuipers EJ, Siersema PD

Publikováno v: Gastrointestinal endoscopy [Gastrointest Endosc] 2006 Jan; Vol. 63 (1), pp. 134-40.